Wednesday, August 25, 2021 9:19:19 AM
https://www.globenewswire.com/news-release/2021/08/25/2286293/0/en/Silo-Pharma-Advances-Psychedelic-Patent-Portfolio.html
Englewood Cliffs NJ, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced the filing of three distinct Patent Cooperation Treaty (PCT) patent applications pertaining to the central nervous system delivery of unique anti-inflammatory therapeutics coupled with psilocybin.
“Each of these PCT applications relates to the continued research and development that Silo Pharma has continued to undertake.” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are excited to have taken this important next step to protect our intellectual property.”
These three PCT applications title listed below along with Silo Pharma’s granted IP expands the potential addressable patient population that needs unique patient-focused therapeutics.
CENTRAL NERVOUS SYSTEM DELIVERY OF PSILOCYBIN
CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS
CENTRAL NERVOUS SYSTEM DELIVERY OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND PSILOCYBIN
The Patent Cooperation Treaty (PCT) is an international treaty with more than 150 Contracting States. The PCT makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single “international” patent application instead of filing several separate national or regional patent applications.
Recent SILO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 09/18/2024 08:19:02 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/18/2024 08:17:30 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/18/2024 08:15:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 10:46:07 AM
- Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD • GlobeNewswire Inc. • 09/10/2024 10:35:00 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 08/21/2024 09:20:42 PM
- Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic • GlobeNewswire Inc. • 08/14/2024 06:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:30:38 PM
- Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide • GlobeNewswire Inc. • 08/07/2024 12:13:00 PM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/26/2024 08:17:36 PM
- Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference • GlobeNewswire Inc. • 07/26/2024 12:20:00 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/25/2024 08:30:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 09:00:38 PM
- Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/22/2024 08:45:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/22/2024 10:06:13 AM
- Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules • GlobeNewswire Inc. • 07/19/2024 12:01:00 PM
- Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15 • GlobeNewswire Inc. • 07/18/2024 12:25:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/17/2024 08:45:59 PM
- Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic • GlobeNewswire Inc. • 07/16/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:15:15 PM
- Silo Pharma Announces Exclusive, Global License for Lead Candidate SPC-15 Targeting PTSD and Stress-Induced Anxiety Disorders • GlobeNewswire Inc. • 07/08/2024 12:45:00 PM
- Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety • GlobeNewswire Inc. • 06/26/2024 12:50:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM